+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 5Years - 75Years
All Genders
Healthy Volunteers
ID06962202

PET Imaging Using Modified Desmopressin mDesmo Cold-Kit to Locate ACTH-Dependent Tumors in Cushing Syndrome

Led by Post Graduate Institute of Medical Education and Research, Chandigarh · Updated on 2025-05-20

100

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Cushing syndrome is a rare endocrine disorder characterized by excessive cortisol production, often caused by ACTH-dependent sources like pituitary tumors Cushing disease or ectopic ACTH secretion. Diagnosing Cushing disease is difficult, especially when tumors are very small microadenomas under 6 mm. Current imaging methods like MRI and invasive tests like bilateral inferior petrosal sinus sampling BIPSS have limited accuracy, complicating tumor localization and surgical planning. This trial aims to evaluate a novel PETCT imaging agent, Gallium-68-modified desmopressin 68Ga-DOTA-mDesmo, which targets receptors overexpressed in corticotropinomas, potentially improving diagnosis and treatment outcomes for ACTH-dependent Cushing syndrome. The study involves using 68Ga-DOTA-mDesmo PETCT imaging to detect and localize pituitary tumors responsible for ACTH-dependent Cushing syndrome. This radiopharmaceutical is injected intravenously and binds selectively to tumor receptors, providing both functional and anatomical images. The formulation is designed as a cold kit enabling easy radiolabelling with Gallium-68 at hospital radiopharmacies. This non-invasive imaging method aims to outperform current diagnostic tests by accurately delineating microadenomas, aiding intra-operative tumor navigation and potentially enhancing surgical remission rates. Participants diagnosed with endogenous Cushing syndrome, aged 5 to 75 years, will undergo PETCT imaging with 68Ga-DOTA-mDesmo on a single day. Researchers will assess the imagings ability to precisely locate corticotropinomas compared to existing methods. Safety evaluations include sterility, pyrogenicity, and radiochemical purity of the radiotracer. The study also monitors renal excretion patterns and tumor-to-background contrast. This observational trials findings may support a more accessible, cost-effective diagnostic tool for better management of ACTH-dependent Cushing syndrome.

CONDITIONS

Brief Title

Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CT

Research Team

R

Rama Walia, DM, Endocrinology

J

Jaya Shukla, Prof, Ph.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here